Skye Bioscience, Inc. Common Stock (SKYE) — Strategic Asset Allocation Index
Skye Bioscience, Inc. Common Stock (SKYE) has a Strategic Asset Allocation Index of 18.3% as of September 2023. Strategic assets (PP&E of $309.83K plus long-term investments of $-) total $309.83K, measured against net assets of $1.70 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Skye Bioscience, Inc. Common Stock (SKYE) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Skye Bioscience, Inc. Common Stock Strategic Asset Allocation Index (2019–2021)
This chart shows how Skye Bioscience, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2021. As of September 2023, the index stands at 18.3%, representing strategic assets of $309.83K against net assets of $1.70 Million USD. For live market cap and overall valuation, see SKYE market cap overview.
Annual Strategic Asset Allocation Index for Skye Bioscience, Inc. Common Stock (2019–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Skye Bioscience, Inc. Common Stock from 2019 to 2021, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See SKYE net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 4.0% | $234.68K | $234.68K | $- | $5.86 Million | ▲ +2.4 pp |
| 2020 | 1.6% | $7.34K | $7.34K | $- | $450.79K | ▲ +1.3 pp |
| 2019 | 0.4% | $1.98K | $1.98K | $- | $548.06K | — |